Bavarian Nordic awaits Covid-19 vaccine funds: Trials on hold until money is there
At the moment, Bavarian Nordic's involvement in the development of a Covid-19 vaccine garners a great deal of attention, but the company emphasizes it does not intend to finance this development itself. It expects external funding.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN
As it stands, Bavarian Nordic won't be the first company to produce a Covid-19 vaccine. Not number two either, but Bavarian doesn't plan to be first.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
